Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | GEN1286 |
| Synonyms | |
| Therapy Description |
GEN1286 is an antibody-drug conjugate (ADC) comprising a bispecific antibody that targets EGFR and cMET linked to the topoisomerase I inhibitor sesutecan, which may induce cytotoxicity against tumor cells expressing EGFR and/or MET and inhibit tumor growth (Cancer Res (2024) 84 (6_Supplement): 6580). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| GEN1286 | PRO1286 | EGFR Antibody 73 MET Antibody 38 | GEN1286 is an antibody-drug conjugate (ADC) comprising a bispecific antibody that targets EGFR and cMET linked to the topoisomerase I inhibitor sesutecan, which may induce cytotoxicity against tumor cells expressing EGFR and/or MET and inhibit tumor growth (Cancer Res (2024) 84 (6_Supplement): 6580). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06685068 | Phase Ib/II | GEN1286 | Trial to Assess the Safety, Tolerability, Pharmacokinetics (PK) and Antitumor Activity of GEN1286 in Participants With Advanced Solid Tumors | Recruiting | USA | 0 |